Exxaro Tiles Ltd IPO: Apply or Not?

On January 2, 2008, 'Ricasil Ceramic Pvt Ltd' was incorporated in Himmatnagar as' Ricasil Ceramic Pvt Ltd. ' On December 9, 2020, a General Meeting was conducted. The company's name was changed to its current name, 'Exxaro Tiles Limited.'

Production Specifications: Double Charge Verified Tiles and Glazed Vitrified Tiles are produced by the business. At the moment, the company primarily offers products in 6 sizes and 1000+ designs. Exxaro Tiles Ltd. has two cutting-edge production plants in Gujarat, Padra and Talod, with a combined installation capacity of 1,32,00,000 sq. mt. p.a. Unit II is one of the largest plants for manufacturing glazed verified tiles under one roof in India. (Source: Brickwork Report) 

Network of the Company: Currently, over 2000 registered dealers supply products for large-scale infrastructure projects. The company has grown its operations to 27 states and 12 countries, including Poland, Italy, and Bosnia.

Revenue from Exports: For fiscal years 2021, 2020, and 2019, the company's revenue from exports contributed 13.88%, 13.51%, and 6.68%, respectively, of all its revenue operations.

Strengths of the Company:

1. Modern production facilities with a significant emphasis on design and quality.
2. Widespread sales and dealers network
3. A large product portfolio with around 1000 designs

Financials of The Company:

Particulars	for the year/period ended (₹ in million)
	31-03-2021	31-03-2020	31-03-2019
Total Assets	3693.14	3870.55	3582.55
Total Revenue	2598.53	2439.64	2440.06
Profit After Tax	152.23	112.59	89.17

IPO Details:

IPO Opening Date	04-08-2021
IPO Closing Date	06-08-2021
Face Value	10₹. Per Equity Share
or the year/period ended (₹ in million)IPO Price	₹118 to ₹120 per equity share
Market Lot	125 Shares
Listing At	BSE, NSE
Issue Size	161.09 Cr.

IPO Time Table:

IPO Open Date	04-08-2021
IPO Close Date	06-08-2021
Allotment Date	11-08-2021
Listing Date	17-08-2021

Recommendation

Apply for only listing gain

(Source:- All details are collected from sebi website)

Windlas Biotech Limited - IPO details

The company was incorporated as 'Windlas Biotech Limited' on February 19, 2001. The Company is one of the leading in the domestic pharmaceutical formulations contract development and manufacturing organization (CDMO) industry in India in terms of revenue. With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage form and significant experience in providing specialized capabilities, including, high potency, controlled substances and low-solubilify. Windlas Biotech provides a comprehensive range of  CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics.

Market Share:- In 2020 Windlas Biotech Limited's market share was approximately 1.5% in terms of revenue in the domestic formulations CDMO industry.

Sales Process:- The company also sell their own branded products in the trade generics and OTC market as well as export generic products to several countries.  

Current Focus:- Windlas Biotech Limited currently focus on launching new complex generic products in chronic therapeutic category linked in to lifestyle related disorders.

Business Verticals:- The Company has three distinct strategic business verticals.

1. CDMO Service and Products
2. Domestic Trade Generics and over-the-counter Brands
3. Exports

All verticals are supported by a network of R&D laboratories and manufacturing facilities which in turn are supported by various functions, including supply chain, inventory, finance and human resources.

Company Strengths:-

1. Leading CDMO in India with a focus on the chronic therapeutic category.
2. Innovative Portfolio of complex generic products supported by robust R&D Capabilities.
3. Efficient and quality compliant manufacturing facilities with significant entry barriers.
4. Strong and long-term relationships with leading Indian pharmaceutical Companies
5. Consistent track record of financial performance
6. Experienced Professional and Technical Qualified Management Team

Financial Reports:-

Particulars	Years (amt in Millions)
	31-12-2020	31-03-2020	31-03-2019
Total Assets	3158.83	3384.88	2981.80
Total Revenue	3230.94	3313.39	3565.76
Profit After Tax	96.74	162.13	638.22

 

IPO Details:-

IPO Opening Date	4/08/2021
IPO Closing Date	06/08/2021
Face Value	5 Rs. Per Equity Share
IPO Price	Rs. 448 to Rs.460 per Share
Market Lot	30 Shares
Listing At	BSE, NSE
Issue Size	401.54 Cr

IPO Table:-

IPO Open Date	04/08/2021
IPO Close Date	06/08/2021
Allotment Date	11/08/2021
Listing Date	17/08/2021

  

IPO Lot Size:-

minimum 1 lot (30 shares, amt 13800 Rs.) maximum 14 lots (420 Shares, amt 193200Rs.)

Our Suggestion 

Recommended for short term

IPO: Glenmark Life Sciences.

COMPANY HISTORY

Glenmark Life Sciences (GLS) is founded in 2011. The company is a leading developer and manufacturer of Active Pharmaceutical Ingredients. GLS partners with the world's 16 of the top 20 generic companies & serves customers in multiple geographies including North America, Europe, Japan, Latin America and ROW.

Financials of The Company

Particulars	Years (amt in lakh)
	31/03/2021	31/03/2020	31/03/2019
Total Assets	19970.75	17256.04	14753.95
Total Revenue	18859.76	15493.03	8868.65
Profit After Tax	3515.81	3130.98	1955.92

Promoters' Holding:

After successful listing, promotors' Holding will be reduced form 100% to 82.84%.

IPO Details

IPO Opening Date	27-07-2021
IPO Closing Date	29-07-2021
IPO PRICE	Rs.695 to Rs.720 per equity share
Minimum Lot Size	20 Shares (1Lot)
Maximum Lot Size	260 Shares (13Lots)
Minimum Investment Amount	14400
Maximum Investment Amount	187200
Listing At	BSE, NSE
Issue Size	Equity Shares of Rs.2 (aggregating up to Rs.1513.6 Cr)
IPO Listing Date	06-08-2021

Grey Market Premium

GLS IPO grey market premium today is Rs.210.

My Recommendation

Every one should apply for this IPO.